Ibrutinib CAS 936563-96-1 Purity >99.5% (HPLC) API
Ingoa matū | Ibrutinib |
Nga kupu taurite | 1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1- kotahi;PCI-32765 |
Tau CAS | 936563-96-1 |
Tūnga Taonga | I roto i te Stock, Production Tauine Up ki Taranata |
Tātai rāpoi | C25H24N6O2 |
Taumaha rāpoi | 440.50 |
Waitohu | Ruifu Chemical |
Tūemi | Whakatakotoranga |
Te ahua | Ma ki te Paura Kiriata-White |
Tautuhinga | IR;HPLC |
Ngaronga i te whakamaroke | <0.50% |
Te toenga i runga i te mura | ≤0.10% |
Konga Taamaha (hei Pb) | ≤20ppm |
Tetahi poke kotahi | ≤0.20% |
Nga poke katoa | <0.50% |
Te Maama / Tikanga Tatauria | >99.5% (HPLC) |
Paerewa Whakamatau | Paerewa hinonga |
Whakamahinga | API |
Mōkī: Pounamu, Peeke konumohe konumohe, 25kg / Cardboard Drum, kia rite ranei ki te hiahia a te kaihoko.
Tikanga Rokiroki:Whakaorangia i roto i nga ipu kua hiri ki te waahi makariri me te maroke;Tiaki i te marama me te makuku.
Ko te Ibrutinib (CAS: 936563-96-1) he aukati i te Bruton tyrosine kinase (BTK) mo te maimoatanga o te mate pukupuku lymphocytic tawhito (CLL) me te lymphoma pūtau koroka (MCL).Ko te MCL me te CLL e rua no te lymphoma kore-Hodgkin o te pūtau-B, he whakakeke, he ngawari ki te hoki.Ko te whakamaarama haumanu e whakamahia nuitia ana kaore i te arohia, a he maha nga wa ka puta nga tauhohenga kino o te reanga 3, 4 ranei.Ka taea e Ibrutinib te whakakotahi me te BTK, he mea tika mo te hanganga, te rereketanga, te whakawhitiwhiti korero me te oranga o nga lymphocytes B, me te aukati i te mahi o te BTK, ka whai hua ki te aukati i te tipu me te oranga o nga pukupuku pukupuku.I tua atu, ka tere te whakauru i muri i te whakahaere a-waha, ka tae te nui o te plasma plasma ki te 1 ~ 2h, a ko nga tauhohenga kino he tohu 1, 2 ranei, ka waiho hei waahanga hou mo te maimoatanga o te CLL me te MCL.I te Whiringa-a-rangi 13, 2013, te US FDA ki te whakatere i te kamupene Johnson & Johnson kua whakaaetia me te United States Imbruvica (ingoa noa: Ibrutinib) mo te maimoatanga o te lymphoma pūtau koroka (MCL).Ibrutinib, i whakawhiwhia e te FDA te mana Haumarutanga pakaruhanga i te Hui-tanguru 2013 ka whakaaetia mo MCL i te Noema 13, 2013 me CLL i te Hui-tanguru 12, 2014, ia.